Half of this number went to a doctor, while 69,000 to 84,000 people have been hospitalized

Reduced risk, slowed progression of retinopathy for Taiwanese patients with type 2 diabetes, dyslipidemia

Reduction in risk for range of critical outcomes greatest for daily dietary fiber intake of 25 to 29 g

Less than 60 percent of patients with diabetes given HbA1c, lipid profile tests in preceding 12 months

A cross continuum of inpatient diabetes care. Hospitals are being incentivized for achieving diabetes care metrics in the patient population in their catchment area which has required them to develop effective healthcare delivery models that impact not only just individual patients but also the patient population as a whole. Hear case studies from Mayo Clinic, MD Anderson, UPMC, Allina Healthcare, Essentia Health and more. Learn about transitioning of care, building and maintaining Inpatient Diabetes Programs and Management, incorporating Triple Aim, diabetes prevention programs, ROI for Tele Diabetes, collaborative diabetes depression models, incorporating SOCIAL DETERMINANTS OF HEALTH measures, financial impact of low literacy on a healthcare system, Cardiovascular risk associated with diabetes and inpatient care, cancer risk associated with diabetes and the inpatient care, managing diabetes in hospitalized patients with chronic Kidney Disease and more. For complete conference details including discounts available for Diabetes In Control Members, click here.

Findings seen in young male, but not female, Japanese workers with type 2 diabetes mellitus

Majority of readmissions occur within seven days of discharge and one-fourth within two days

We are often amazed when someone is diagnosed with T1DM when there is no family history. That is because the disease is about 15 times more common in siblings of a patient with diabetes than in the general population. In addition, siblings have an average risk of 6% of developing …

I have a patient who has type 2 diabetes. He was started on long-acting insulin 8 months ago. Before adding the insulin, he was taking a daily GLP-1. He had experienced diabetic ketoacidosis (DKA) while on a SGLT-2, and did not tolerate metformin due to GI side effects. Therefore, these …

Rachele Berria MD, PhD is Vice President and Head, Diabetes Medical Unit at Sanofi, Bridgewater, New Jersey. She has a medical degree (undergrad/graduate combined program) and Obstetrics and Gynecology Board Certification from the University of Cagliari School of Medicine, Italy. Her many other educational accomplishments include a Master of Science in Clinical Investigation from the University of Texas Health Science Center at San Antonio, Texas; Ph.D. Degree in Medical Pathophysiology and Pharmacology from the University of Pisa School of Medicine, Italy; a Fellowship in Diabetes and Metabolism from the Internal Medicine Department, University of Texas Health Science Center at San Antonio, Texas;  and a Master Practitioner Certification in Effective Communication from the Neurolinguistic Programming Center of New York City, NY.